Impact of extramedullary plasmacytoma on outcomes in patients with relapsed refractory multiple myeloma treated with talquetamab: U.S. Myeloma Immunotherapy Consortium.
Author / Organization: Afrough A, Pasvolsky O, Portuguese AJ, Zanwar S, Gaballa MR, Sannareddy A, Dima D, Goel U, Ali HM, Julian K, De Menezes Silva Corraes A, Janakiram M, Goldsmith S, Davis JA, Green K, Biran N, Fogel L, Zolotov E, Herr MM, Hassan H, Shune L, Kort J, Ye C, Bal S, Costa LJ, Joiner L, Al Hadidi S, Khan AM, Raza S, Anwer F, Khouri J, Banerjee R, Cassano Cassano R, Sidana S, Rana MS, Mikkilineni L, Hosoya H, Atrash S, Ferreri C, Varga C, Sborov DW, Midha S, Nadeem O, Grajales-Cruz A, Baz R, Blue B, Freeman C, Locke FL, Patel KK, Lin Y, Kumar SK, Hansen DK, Anderson LD Jr, Voorhees PM, Castaneda-Puglianini O
| File Format | PDF (Portable Document Format) |
|---|---|
| Publication Year | 2026 |
| Source Host |
PubMed Central
(pmc.ncbi.nlm.nih.gov)
|
| License / Terms | Open Access / Creative Commons |
Ready for Immediate Access
Your selected document is ready for instant access with zero mandatory waiting period.